Raumedic reorganizes its management

Als neuer Vorstandsvorsitzender der Raumedic-Gruppe will Martin Bayer künftig vor allem den US-Markt verstärkt bearbeiten. / As the new Chairman of the Raumedic Group, Martin Bayer will be focusing on growth on the US market.

Martin Schenkel ist seit Februar Vorstandsmitglied der Raumedic AG. / Martin Schenkel was newly appointed as a Raumedic AG board member in February.

Martin Bayer, until recently sole board member of Raumedic AG, was appointed chairman of the entire group in February 2018. Further, Bayer moved his office to North America, where he will be serving as President and CEO of Raumedic Inc. at the Mills River site. After completing the construction of an administration and production building in North Carolina, the company with Bavarian roots now is looking to quickly establish itself on the world’s largest medical technology market, while pursuing a globally consistent market cultivation strategy.

“I look forward to devoting myself to this task, and being on site will provide me with the best conditions,” the 56-year-old explains the reasoning behind his decision to move to the US. Under Martin Bayer’s leadership the medical technology company has more than doubled its sales the past ten years, growing the number of employees from 360 to over 700 worldwide. Given this growth and his new office in the US, Bayer points out how crucial it is that collaboration with his colleagues in Germany continues to run smoothly. To ensure this, regular video conferences with the Helmbrechts headquarters have already been scheduled.

Additionally, Martin Schenkel, a seasoned member of management, was newly appointed as member of the board of Raumedic AG. As Chief Operating Officer, Schenkel is responsible for production at all Raumedic sites. In his new role, he is now also the man in charge of the company headquarters, reporting to group CEO Martin Bayer. In this process of reorganization, the management team of Raumedic AG will be further expanded in the next months.